Neoleukin Therapeutics, Inc (NLTX)

Etorro trading 970x250
Neoleukin Therapeutics, Inc (NLTX) Logo

About Neoleukin Therapeutics, Inc

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Address: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102

Neoleukin Therapeutics, Inc News and around…

Latest news about Neoleukin Therapeutics, Inc (NLTX) common stock and company :

Neoleukin Therapeutics Becomes Oversold (NLTX)
19 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
12 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). The presentation highlights preclinical data on NL-201 alone and in seve

Neoleukin Therapeutics to Present at Upcoming Investor Conferences
09 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in two upcoming investor conferences. Presentation Details: Event: Stifel 2021 Virtual Healthcare ConferenceDate: Tuesday, November 16, 2021Time: 3:20 to 3:50 p.m. ESTFormat: Fireside chat Event: Piper Sandler 33rd Annual Virtual Healthc

Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
04 Nov, 2021 Yahoo! Finance

– NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 – – Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data – – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in 2022 – SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporat

Here's What Neoleukin Therapeutics, Inc.'s (NASDAQ:NLTX) Shareholder Ownership Structure Looks Like
25 Oct, 2021 Yahoo! Finance

A look at the shareholders of Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) can tell us which group is most powerful...

Sum Up The Pieces: PBSM Could Be Worth $46
13 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.46 per unit.

Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
01 Oct, 2021 Yahoo! Finance

SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) taking place November 10-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. “Presentations by our scientists a

Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Co
29 Sep, 2021 FinancialContent
Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern
29 Sep, 2021 Yahoo! Finance

– Single intranasal dose of NL-CVX1 in mice prevents infection by multiple variants of SARS-CoV-2 – – Transgenic mice that are protected from disease by NL-CVX1 remain resistant to rechallenge after one month – SEATTLE, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data highlighting the ability of its de novo protein d

Analysts Expect VTWG Will Reach $269
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $268.83 per unit.

Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research
09 Sep, 2021 FinancialContent
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
60 Biggest Movers From Friday
30 Aug, 2021 FinancialContent

Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss ...

35 Stocks Moving In Friday's Mid-Day Session
27 Aug, 2021 FinancialContent

Gainers Support.com, Inc. (NASDAQ: SPRT) shares climbed 87% to $36.83 on abnormally high volume amid continued volatility. The ...

Top Buys by Directors: Drachman's $933.5K Bet on NLTX
27 Aug, 2021 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Friday 8/27 Insider Buying Report: NLTX, CYXT
27 Aug, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Top Buys by Top Brass: CEO Drachman's $933.5K Bet on NLTX
27 Aug, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Relative Strength Alert For Neoleukin Therapeutics
18 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Analysts Anticipate 23% Upside For IWO
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $373.26 per unit.

Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update
05 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
04 Aug, 2021 FinancialContent

Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company ...

Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
04 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
27 Jul, 2021 FinancialContent

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group ...

Neoleukin Therapeutics, Inc (NLTX) is a NASDAQ Common Stock listed in , ,

970x250